Literature DB >> 23678676

Schedules of controlled substances: temporary placement of three synthetic cannabinoids into Schedule I. Final order.

.   

Abstract

The Deputy Administrator of the Drug Enforcement Administration (DEA) is issuing this final order to temporarily schedule three synthetic cannabinoids under the Controlled Substances Act (CSA) pursuant to the temporary scheduling provisions of 21 U.S.C. 811(h). The substances are (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144), [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (5-fluoro-UR-144, XLR11) and N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA, AKB48). This action is based on a finding by the Deputy Administrator that the placement of these synthetic cannabinoids and their salts, isomers and salts of isomers into Schedule I of the CSA is necessary to avoid an imminent hazard to the public safety. As a result of this order, the full effect of the CSA and the Controlled Substances Import and Export Act (CSIEA) and their implementing regulations including criminal, civil and administrative penalties, sanctions and regulatory controls of Schedule I substances will be imposed on the manufacture, distribution, possession, importation, and exportation of these synthetic cannabinoids.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23678676

Source DB:  PubMed          Journal:  Fed Regist        ISSN: 0097-6326


  15 in total

1.  Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and Abuse Potential.

Authors:  Sherrica Tai; William E Fantegrossi
Journal:  Curr Addict Rep       Date:  2014-06-01

2.  Thermolytic Degradation of Synthetic Cannabinoids: Chemical Exposures and Pharmacological Consequences.

Authors:  Brian F Thomas; Timothy W Lefever; Ricardo A Cortes; Megan Grabenauer; Alexander L Kovach; Anderson O Cox; Purvi R Patel; Gerald T Pollard; Julie A Marusich; Richard C Kevin; Thomas F Gamage; Jenny L Wiley
Journal:  J Pharmacol Exp Ther       Date:  2017-01-13       Impact factor: 4.030

3.  Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles.

Authors:  Jenny L Wiley; Julie A Marusich; Timothy W Lefever; Megan Grabenauer; Katherine N Moore; Brian F Thomas
Journal:  Neuropharmacology       Date:  2013-08-02       Impact factor: 5.250

4.  First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry.

Authors:  Ariane Wohlfarth; Shaokun Pang; Mingshe Zhu; Adarsh S Gandhi; Karl B Scheidweiler; Hua-fen Liu; Marilyn A Huestis
Journal:  Clin Chem       Date:  2013-09-06       Impact factor: 8.327

5.  Δ9-Tetrahydrocannabinol-like effects of novel synthetic cannabinoids found on the gray market.

Authors:  Michael B Gatch; Michael J Forster
Journal:  Behav Pharmacol       Date:  2015-08       Impact factor: 2.293

6.  Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22.

Authors:  George Behonick; Kevin G Shanks; Dennis J Firchau; Gagan Mathur; Charles F Lynch; Marcus Nashelsky; David J Jaskierny; Chady Meroueh
Journal:  J Anal Toxicol       Date:  2014-05-29       Impact factor: 3.367

7.  Simultaneous quantification of 20 synthetic cannabinoids and 21 metabolites, and semi-quantification of 12 alkyl hydroxy metabolites in human urine by liquid chromatography-tandem mass spectrometry.

Authors:  Karl B Scheidweiler; Marilyn A Huestis
Journal:  J Chromatogr A       Date:  2013-12-30       Impact factor: 4.759

8.  Development of a high-performance liquid chromatography-tandem mass spectrometry method for the identification and quantification of CP-47,497, CP-47,497-C8 and JWH-250 in mouse brain.

Authors:  Kimberly L Samano; Justin L Poklis; Aron H Lichtman; Alphonse Poklis
Journal:  J Anal Toxicol       Date:  2014-05-09       Impact factor: 3.367

9.  Synthetic cannabinoid use among patients in residential substance use disorder treatment: prevalence, motives, and correlates.

Authors:  Erin E Bonar; Lisham Ashrafioun; Mark A Ilgen
Journal:  Drug Alcohol Depend       Date:  2014-07-17       Impact factor: 4.492

10.  High-resolution mass spectrometric metabolite profiling of a novel synthetic designer drug, N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135), using cryopreserved human hepatocytes and assessment of metabolic stability with human liver microsomes.

Authors:  Adarsh S Gandhi; Ariane Wohlfarth; Mingshe Zhu; Shaokun Pang; Marisol Castaneto; Karl B Scheidweiler; Marilyn A Huestis
Journal:  Drug Test Anal       Date:  2014-05-14       Impact factor: 3.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.